Europe’s Largest Initiative to Accelerate Therapy Development for COVID-19 Launched

Europe’s Largest Initiative to Accelerate Therapy Development for COVID-19 Launched

A European consortium has been launched to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.

Corona Accelerated R&D in Europe (CARE), is the largest undertaking of its kind dedicated to creating effective therapies with a positive safety profile and repurposing existing therapies for the pandemic.

It aims to boost R&D by bringing together the leading expertise and projects of 37 teams from academic, non-profit research institutions and pharmaceutical companies into a comprehensive drug discovery engine. It will integrate partners’ COVID-19 projects ongoing since February 2020.

The five-year project is supported by the Innovative Medicines Initiative (IMI) and has received a grant of €77.7 million, funded by cash contributions from the European Union and contributions from 11 European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-associated partners.

Researchers will undertake drug repositioning; small-molecule drug discovery based on in silico screening and profiling of candidate compounds; and virus neutralising antibody discovery.

After testing in the laboratory, the project will advance the most promising drug candidates to clinical trials in humans.

Read on mobihealthnews.com


Deploy this technology today



Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on Mar 28, 2024 at 3:00am